Each week we highlight five things affecting the life sciences industry. Here’s the latest.
FDA signals more flexible approach to previously rejected drugs
- The U.S. Food and Drug Administration is increasingly allowing companies to resubmit previously rejected drug applications (complete response letters) without new data, signaling a more flexible and potentially approval-friendly regulatory stance, especially for rare disease treatments.
- According to Endpoints News, this shift has sparked discussion among industry experts, with recent reversals raising questions about how approval decisions are being shaped and the balance between external considerations and scientific review.
Company raises upsized IPO to fuel late-stage heart drugs
- A heart health company recently completed an upsized $400 million initial public offering (with a potential additional $60 million if underwriters take their full option in the next 30 days) by pricing shares at the top of its range, strengthening cash position to support pipeline development.
- The funds will advance three cardiovascular drug candidates toward Phase 3 trials and support use of its artificial intelligence-enabled platform for clinical development, though potential FDA hesitation on digital clinical endpoints could impact timelines, according to Fierce Biotech.
Liaison program between MHRA and FDA announced
- The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the FDA launched a new liaison program with dedicated reciprocal staff roles to strengthen day-to-day collaboration, improve scientific exchange and better coordinate responses to emerging regulatory challenges.
- The initiative aims to accelerate alignment on medicines, devices and new technologies to speed patient access and reduce regulatory friction, while both agencies retain independent decision-making authority.
Large pharma company expands immunology pipeline with acquisition
- A large pharmaceutical company will acquire a private biotech for up to $1 billion, gaining three preclinical anti-inflammatory/immunology assets as part of a strategy to bolster its early-stage pipeline.
- The deal expands the pharmaceutical company’s growing immunology focus following recent mergers and acquisitions activity and supports a broader push into immune-mediated diseases, complementing its existing late-stage portfolio, reports BioSpace.
UK regulator launches AI sandbox for safer medicine development
- The UK’s MHRA has launched a new AI sandbox that allows researchers and developers to test AI tools in a controlled environment to improve medicine safety, predict side effects earlier and support faster drug development.
- According to Digital Health News, the initiative aims to generate evidence on how AI can assess drug behavior, enhance safety evaluations across diverse patient groups and reduce reliance on animal testing while helping regulators evaluate the reliability of these technologies.
For more insights in life sciences, check out RSM’s industry outlook.
